Dashboard
Manage Tickers

OVID Ovid Therapeutics Inc.

Nasdaq ovidrx.com


$ 1.61 $ 0.00 (0 %)    

Thursday, 23-Oct-2025 06:03:18 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 603.70 $ 0.00 (0 %)
DIA $ 464.76 $ 0.00 (0 %)
SPY $ 666.87 $ 0.00 (0 %)
TLT $ 91.60 $ 0.00 (0 %)
GLD $ 377.30 $ 0.00 (0 %)
$ 1.61
$ 1.61
$ 1.57 x 650
$ 1.64 x 62
-- - --
$ 0.24 - $ 2.01
1,318,701
na
114.49M
$ 1.12
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-11-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-08-2024 12-31-2023 10-K
8 11-03-2023 09-30-2023 10-Q
9 08-04-2023 06-30-2023 10-Q
10 05-05-2023 03-31-2023 10-Q
11 03-13-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-15-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-15-2021 12-31-2020 10-K
20 11-13-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-11-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-07-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 03-07-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-08-2018 03-31-2018 10-Q
31 03-29-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-10-2017 06-30-2017 10-Q
34 06-13-2017 03-31-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

reported-earlier-ovid-therapeutics-announces-topline-results-from-its-phase-1-healthy-volunteer-study-evaluating-the-safety-tolerability-pharmacokinetic-and-pharmacodynamic-activity-of-ov329-a-next-generation-gaba-at-inhibitor-being-developed-for-drug-resistant-epilepsies-advancing-to-phase-2a-for-drug-resistant-epilepsy
Reported Earlier: Ovid Therapeutics Announ...
10/03/2025 14:50:22

An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multi...

reported-earlier-ovid-therapeutics-has-entered-into-a-securities-purchase-agreement-for-a-private-investment-in-public-equity-financing-that-is-expected-to-result-in-gross-proceeds-of-up-to-175m-to-advance-brain-disease-therapies
Reported Earlier: Ovid Therapeutics Has En...
10/03/2025 14:47:54

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain co...

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
10/03/2025 12:08:34

ovid-therapeutics-regains-compliance-with-nasdaq
Ovid Therapeutics Regains Compliance With ...
09/16/2025 12:14:59

-SEC Filing

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/13/2025 21:06:15

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/13/2025 17:06:22

ovid-therapeutics-q2-eps-006-beats-016-estimate-sales-6272m-beat-76667k-estimate
Ovid Therapeutics Q2 EPS $(0.06) Beats $(0...
08/13/2025 12:13:06

Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0...

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
07/21/2025 21:06:05

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
07/17/2025 17:06:01

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
06/27/2025 21:05:51

ovid-therapeutics-enters-agreement-with-immedica-pharma-ab-immedica-to-pay-7m-in-cash-to-acquire-100-of-royalty-ganaxolone-rights-held-by-ovid
Ovid Therapeutics Enters Agreement with Im...
06/25/2025 12:09:26

hc-wainwright--co-maintains-buy-on-ovid-therapeutics-lowers-price-target-to-15
HC Wainwright & Co. Maintains Buy on Ovid ...
05/27/2025 11:01:41

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and lowers the price...

ovid-therapeutics-q1-eps-014-inline-sales-13000k-beat-5000k-estimate
Ovid Therapeutics Q1 EPS $(0.14), Inline, ...
05/13/2025 12:10:38

Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This i...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
04/24/2025 21:05:49

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
04/23/2025 21:05:54

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
04/09/2025 12:07:29

btig-maintains-buy-on-ovid-therapeutics-lowers-price-target-to-4
BTIG Maintains Buy on Ovid Therapeutics, L...
03/24/2025 13:28:39

BTIG analyst Thomas Shrader maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and lowers the price target from $5 to $4.

wedbush-maintains-outperform-on-ovid-therapeutics-lowers-price-target-to-3
Wedbush Maintains Outperform on Ovid Thera...
03/12/2025 14:27:05

Wedbush analyst Laura Chico maintains Ovid Therapeutics (NASDAQ:OVID) with a Outperform and lowers the price target from $4 ...

ovid-therapeutics-q4-2024-gaap-eps-013-beats-016-estimate-sales-76k-miss-189286k-estimate
Ovid Therapeutics Q4 2024 GAAP EPS $(0.13)...
03/11/2025 12:13:14

oppenheimer-upgrades-ovid-therapeutics-to-outperform-announces-4-price-target
Oppenheimer Upgrades Ovid Therapeutics to ...
01/29/2025 18:04:49

Oppenheimer analyst Francois Brisebois upgrades Ovid Therapeutics (NASDAQ:OVID) from Perform to Outperform and announces $4 ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION